Elevating Expectations: Vericiguat in Heart Failure with Reduced Ejection Fraction

A BSTRACT Introduction: Heart failure (HF) with reduced ejection fraction (EF) poses high morbidity and mortality. Guidelines Directed Medical Therapy (GDMT) is essential, yet many patients experience significant symptoms. Vericiguat, a soluble guanylate cyclase stimulator, may serve as an adjunctive therapy by enhancing the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway. Methods: This observational cohort study involved 100 participants with stage C HF and reduced EF (<40%), divided into two groups: 48 receiving vericiguat plus GDMT and 52 receiving GDMT alone. Primary outcomes included mortality, HF admissions, and changes in EF over 6 months. Results: Mortality rates were lower in the vericiguat group (10.4%) than in GDMT alone (17.3%, P = 0.32). HF admissions were reduced in the vericiguat group (25.0% vs 38.5%, P < 0.14), with significantly fewer mean HF admissions per patient (0.7 vs 1.2, P = 0.03). EF improved significantly more with vericiguat (+5.1% vs +2.3%, P < 0.01). Conclusion: Vericiguat may enhance management of stage C HF patients with reduced EF. Larger randomized controlled trials are needed to confirm these findings.